Post-Inflammatory Hyperpigmentation (Investigational)
Highly investigational adjunct for refractory PIH; no clinical study found; sun protection, topical hypopigmenting agents, and chemical peels remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for post-inflammatory hyperpigmentation. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No clinical study of leech therapy for this condition was identified. Evidence-based first-line management is rigorous broad-spectrum sunscreen use, treatment of the underlying inflammation, topical hydroquinone (4 percent) often combined with retinoid and corticosteroid (Kligman regimen), azelaic acid, tranexamic acid (topical or low-dose oral), and for resistant cases chemical peels (glycolic, salicylic) or laser. Many cases also fade spontaneously over 6-24 months.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Paradoxical worsening of hyperpigmentation (post-inflammatory hyperpigmentation can be triggered by ANY skin inflammation, including leech bites)
- Permanent scarring at bite sites in patients with darker skin types
- Who should not consider this
- Patients with Fitzpatrick skin types IV-VI without first trying medical therapy (high risk of PIH from leech bites themselves)
- Patients who have not had a full trial of sunscreen + topical lighteners for at least 3-6 months
- Patients with active underlying inflammation (the cause must be treated first)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- What to ask your clinician
- Is my hyperpigmentation truly post-inflammatory, or could it be melasma or another pigmentary disorder?
- Have I had a proper trial of sunscreen, hydroquinone, retinoid, and azelaic acid?
- What is the risk that leech bites themselves cause more hyperpigmentation in my skin type?
- Have chemical peels or laser been considered?
- What is the published evidence base for leeches in PIH specifically?
- How will success be measured — colorimetry, photographs, both?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Sudden spread of pigmentation, new dark patches with irregular borders (possible melanoma)
- Rapidly enlarging or asymmetric pigmented lesion
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for hyperpigmentation — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace sunscreen, topical lighteners, and treatment of the underlying inflammation.
- It does not prevent recurrence if the original inflammatory cause continues.
- It may worsen PIH in darker skin by adding new inflammatory bite sites.
- It does not have controlled-trial evidence and is unlikely to outperform proven topical therapy.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- L81.9, L81.0
- Safety tier
- Medium
Evidence Summary
Post-inflammatory hyperpigmentation, common in Fitzpatrick IV-VI skin, follows acne, eczema, and other inflammatory dermatoses. Management per dermatologic consensus includes strict photoprotection, treating the underlying inflammatory dermatosis, and topical hydroquinone, retinoids, azelaic acid, niacinamide, and chemical peels (with caution in darker skin types). No clinical study of leech therapy for post-inflammatory hyperpigmentation, controlled or uncontrolled, was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov or the Baskova and Isakhanyan (2004) monograph; its use is investigational and any rationale is mechanistic only. PIH typically resolves spontaneously over 6-18 months with photoprotection alone, and treatment-resistant cases are rare. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active inflammatory dermatosis at site (treat underlying condition first)
- Recent chemical peel or laser (<6 weeks)
- Fitzpatrick V-VI skin with hypertrophic scar tendency
- Concurrent topical corticosteroid use
Related Conditions
Melasma (Investigational Adjunct)
Highly investigational adjunct for refractory melasma; uncontrolled reports only; sun protection, hydroquinone, tretinoin, tranexamic acid, and chemical peels remain primary.
Severe Inflammatory Acne Vulgaris
Highly investigational use for severe nodulocystic acne refractory to isotretinoin; small Ayurvedic studies only, none in refractory disease, and scarring risk concerns.
Rosacea (Erythematotelangiectatic)
Investigational use for erythematotelangiectatic rosacea; no clinical study of leech therapy was identified.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.